Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095394 · ClinicalTrials.gov registry record · Phase 3
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
NCT00095394: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00095394 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 645 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095394, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
Study Summary
The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
Interventions
- DRUG Irbesartan/HCTZ
- DRUG Irbesartan monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
What the finished NCT00095394 record still lists
NCT00095394 is an interventional study that assigns participants to a tested intervention. The registered 645 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 2 interventions - of which Irbesartan/HCTZ is the first listed.
NCT00095394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00095394 about?
NCT00095394 is a clinical study titled "Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension". The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate th...
What is the current status of trial NCT00095394?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. The study started on 2004-09. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00095394?
The interventions under investigation include: Irbesartan/HCTZ (DRUG), Irbesartan monotherapy (DRUG).
Who is sponsoring clinical trial NCT00095394?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00095394's enrollment target sits among peer trials
645 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia